<div class="container text"> Selection is a key mechanism of evolution like Darwin defined it. Biodiversity and life as we know it in all its complexity is scientificly not explicable without it. We wanted to design a system able to generate an Evobody that can gain affinity towards any target protein it is confronted with. So what better way is there to design our system than copying one of evolutions core principles and letting the bacteria with the best Evobody emerge by itself?<br>
−
Having a library of Evobodies as well as a mutation system is a great way to guarantee a high variety of binding proteins.
+
Having a <a href="https://2016.igem.org/Team:Bielefeld-CeBiTec/Project/Library">library</a> of Evobodies as well as a <a href="https://2016.igem.org/Team:Bielefeld-CeBiTec/Results/Mutation">mutation system</a> is a great way to guarantee a high variety of binding proteins.
However, there is still the need of a screening method to separate Evobodies that show affinity to the target protein from those
However, there is still the need of a screening method to separate Evobodies that show affinity to the target protein from those
that do not. As we wanted our whole system to work <i>in vivo</i> utilizing directed evolution we settled for three different
that do not. As we wanted our whole system to work <i>in vivo</i> utilizing directed evolution we settled for three different
The <a href="#">bacterial two-hybrid system</a>, our main approach, consists of two fusion proteins and a reporter gene that grants selective advantage. One
<figcaption class="figure-caption"><b>Figure 1: Illustration of the bacterial two-hybrid system.</b> At first two fusion proteins were expressed. The first protein contains a DNA binding domain (cI(434)) with the target protein (<b>1</b>). The second fusion protein contains the activation domain (RpoZ) with our created binding protein (<b>2</b>). At first the DNA binding domain binds at the specific binding site upstream of the reporter (<b>3</b>). If the binding protein can interact with our target (<b>4</b>) the RNA Polymerase I can be recruited and binds to the promoter (<b>5</b>). The result is the expression of the reporter gene, in example the beta-lactamase(<b>6</b>). No binding between the target and the binding protein (<b>7</b>) leads to no expression of the reporter gene (<b>8</b>). At the end only the bacteria survive with the activated reporter. These bacteria you can use to produce a lot of the binding proteins against your specific target (<b>9</b>).
+
</figcaption>
+
</figure> </center>
+
<div class="container text">The <a href="https://2016.igem.org/Team:Bielefeld-CeBiTec/Project/Selection/Bacterial_Two-Hybrid_System">bacterial two-hybrid system</a>, our main approach, consists of two fusion proteins and a reporter gene that grants selective advantage. One
fusion protein is the target protein fused to a DNA-binding domain while the other comprises the Evobody consisting of a binding protein with a RNA polymerase subunit. The
fusion protein is the target protein fused to a DNA-binding domain while the other comprises the Evobody consisting of a binding protein with a RNA polymerase subunit. The
DNA-binding domain that is connected to the target protein binds upstream of the reporter gene, in our case coding for beta-lactamase.
DNA-binding domain that is connected to the target protein binds upstream of the reporter gene, in our case coding for beta-lactamase.
If there is a certain affinity between the Evobody and the target protein, the polymerase subunit of the Evobody recruits the full enzyme and subsequently the beta-lactamase
If there is a certain affinity between the Evobody and the target protein, the polymerase subunit of the Evobody recruits the full enzyme and subsequently the beta-lactamase
−
is expressed. Cultivated in an increasing concentration of ampicillin, only those bacteria expressing enough beta-lactamase will prevail. Since the expression
+
is expressed (<a href="https://2016.igem.org/Team:Bielefeld-CeBiTec/Project/Selection/Motivation#badran">Badran et al. 2016</a>). Cultivated in an increasing concentration of ampicillin, only those bacteria expressing enough beta-lactamase will prevail. Since the expression
of beta-lactamase correlates to the affinity between Evobody and binding protein we can use the best grown bacteria to determine the sequence of the Evobody
of beta-lactamase correlates to the affinity between Evobody and binding protein we can use the best grown bacteria to determine the sequence of the Evobody
The <a href="#">split-protein</a> approach is also based on beta-lactamase as a resistance to ampicillin. The general idea is, to split a reporter protein
into two non-functional subunits. Then, a translational fusion between one half of the split-protein respectively and one of the two allegedly binding proteins
+
<figcaption class="figure-caption"><b>Figure 2: Illustration of the split-protein system.</b> Only in case of the Evobody showing affinity towards the target protein the functionality of the split beta-lactamase(<b>10</b>) is restored, granting a ampicillin resistance to the bacterium that generates the Evobody.
−
is created. In case of succesful binding between the proteins, the fused split-protein halfes should therefore restore the functional reporter protein. As afore mentioned we
+
</figcaption>
−
decided for beta-lactamase as a reporter since it allows for the application of selective pressure. Each, the Evobody and the target protein, are fused to a different
+
</figure> </center>
+
The <a href="https://2016.igem.org/Team:Bielefeld-CeBiTec/Project/Selection/SplitBetaLactamaseHitchHiker#split">split-protein</a> approach is also based on beta-lactamase as a resistance to ampicillin. The general idea is, to split a reporter protein
+
into two non-functional subunits. Then, a translational fusion of one half of the split-protein respectively and one of the two allegedly binding proteins
+
is created. In case of successful binding between the proteins, the fused split-protein halves should therefore restore the functional reporter protein. As afore mentioned we
+
chose beta-lactamase as a reporter, as it allows the application of selective pressure. Both, the Evobody and the target protein are fused to a different
half of the split-beta-lactamase. In case of a successful binding Evobody the bacterium in concern should be granted an ampicillin resistance due to a restored and
half of the split-beta-lactamase. In case of a successful binding Evobody the bacterium in concern should be granted an ampicillin resistance due to a restored and
−
functional beta-lactamase.
+
functional beta-lactamase (<a href="https://2016.igem.org/Team:Bielefeld-CeBiTec/Project/Selection/Motivation#galarneau">Galarneau et al. 2002</a>).
The <a href="https://2016.igem.org/Team:Bielefeld-CeBiTec/Project/Selection/SplitBetaLactamaseHitchHiker#hitch">TAT-hitchhiker selection</a> works on a similar premise as the split-protein. Yet, in this case the beta-lactamase is not divided into two subunits
−
The <a href="#">TAT-hitchhiker selection</a> works on a similar premise as the split-protein. But in this case the beta-lactamase is not divided into two subunits
+
but instead its natural export signals are removed. this modified beta-lactamase forms a translational unit with the target protein whilst a signal peptide
but instead its natural export signals are removed. this modified beta-lactamase forms a translational unit with the target protein whilst a signal peptide
for the Tat (Twin-Arginine Translocation) pathway is attached to the Evobody. Only in case of a funtionally binding Evobody to the target protein is the
for the Tat (Twin-Arginine Translocation) pathway is attached to the Evobody. Only in case of a funtionally binding Evobody to the target protein is the
beta-lactamase exported into the periplasm where it can counteract the ampicillin. Since the Tat pathway only exports correctly folded proteins, this approach also
beta-lactamase exported into the periplasm where it can counteract the ampicillin. Since the Tat pathway only exports correctly folded proteins, this approach also
−
provides an option to check if the proteins are expressed as we hope they are.
+
provides an option to check if the proteins are expressed as we predicted (<a href="https://2016.igem.org/Team:Bielefeld-CeBiTec/Project/Selection/Motivation#waraho">Waraho, Dujduan & DeLisa, Matthew P. 2009</a>).
<br>
<br>
<br>
<br>
−
In summary, we wanted a selection system to screen for Evobodies with high affinity to the target protein while being functional <i>in vivo</i>. We chose three approaches, the
+
In summary, we wanted a selection system to screen for Evobodies with high affinity to the target protein while being functional <i>in vivo</i>. We chose three approaches, of which the <a href="https://2016.igem.org/Team:Bielefeld-CeBiTec/Project/Selection/Bacterial_Two-Hybrid_System">bacterial two-hybrid system</a> proved to be the <a href="*">most promising system</a>.
−
<a href="#">bacterial two-hybrid system</a>, the <a href="#">split-protein</a> approach and the <a href="#">TAT-hitchhiker selection</a>.
<li id="badran">Badran, Ahmed H.; Guzov, Victor M.; Huai, Qing; Kemp, Melissa M.; Vishwanath, Prashanth; Kain, Wendy et al. (2016): Continuous evolution of Bacillus thuringiensis toxins overcomes insect resistance. In: Nature 533 (7601), S. 58–63. DOI: 10.1038/nature17938.</li>
+
<li id="galarneau">Galarneau, Andre; Primeau, Martin; Trudeau, Louis-Eric; Michnick, Stephen W. (2002): Beta-lactamase protein fragment complementation assays as in vivo and in vitro sensors of protein protein interactions. In: Nature biotechnology 20 (6), S. 619–622. DOI: 10.1038/nbt0602-619.</li>
+
<li id="waraho">Waraho, Dujduan; DeLisa, Matthew P. (2009): Versatile selection technology for intracellular protein-protein interactions mediated by a unique bacterial hitchhiker transport mechanism. In: Proceedings of the National Academy of Sciences of the United States of America 106 (10), S. 3692–3697. DOI: 10.1073/pnas.0704048106.</li>
Selection is a key mechanism of evolution like Darwin defined it. Biodiversity and life as we know it in all its complexity is scientificly not explicable without it. We wanted to design a system able to generate an Evobody that can gain affinity towards any target protein it is confronted with. So what better way is there to design our system than copying one of evolutions core principles and letting the bacteria with the best Evobody emerge by itself?
Having a library of Evobodies as well as a mutation system is a great way to guarantee a high variety of binding proteins.
However, there is still the need of a screening method to separate Evobodies that show affinity to the target protein from those
that do not. As we wanted our whole system to work in vivo utilizing directed evolution we settled for three different
approaches to screen for functional Evobodies:
Overview
Figure 1: Illustration of the bacterial two-hybrid system. At first two fusion proteins were expressed. The first protein contains a DNA binding domain (cI(434)) with the target protein (1). The second fusion protein contains the activation domain (RpoZ) with our created binding protein (2). At first the DNA binding domain binds at the specific binding site upstream of the reporter (3). If the binding protein can interact with our target (4) the RNA Polymerase I can be recruited and binds to the promoter (5). The result is the expression of the reporter gene, in example the beta-lactamase(6). No binding between the target and the binding protein (7) leads to no expression of the reporter gene (8). At the end only the bacteria survive with the activated reporter. These bacteria you can use to produce a lot of the binding proteins against your specific target (9).
The bacterial two-hybrid system, our main approach, consists of two fusion proteins and a reporter gene that grants selective advantage. One
fusion protein is the target protein fused to a DNA-binding domain while the other comprises the Evobody consisting of a binding protein with a RNA polymerase subunit. The
DNA-binding domain that is connected to the target protein binds upstream of the reporter gene, in our case coding for beta-lactamase.
If there is a certain affinity between the Evobody and the target protein, the polymerase subunit of the Evobody recruits the full enzyme and subsequently the beta-lactamase
is expressed (Badran et al. 2016). Cultivated in an increasing concentration of ampicillin, only those bacteria expressing enough beta-lactamase will prevail. Since the expression
of beta-lactamase correlates to the affinity between Evobody and binding protein we can use the best grown bacteria to determine the sequence of the Evobody
which then could be used for production.
Figure 2: Illustration of the split-protein system. Only in case of the Evobody showing affinity towards the target protein the functionality of the split beta-lactamase(10) is restored, granting a ampicillin resistance to the bacterium that generates the Evobody.
The split-protein approach is also based on beta-lactamase as a resistance to ampicillin. The general idea is, to split a reporter protein
into two non-functional subunits. Then, a translational fusion of one half of the split-protein respectively and one of the two allegedly binding proteins
is created. In case of successful binding between the proteins, the fused split-protein halves should therefore restore the functional reporter protein. As afore mentioned we
chose beta-lactamase as a reporter, as it allows the application of selective pressure. Both, the Evobody and the target protein are fused to a different
half of the split-beta-lactamase. In case of a successful binding Evobody the bacterium in concern should be granted an ampicillin resistance due to a restored and
functional beta-lactamase (Galarneau et al. 2002).
The TAT-hitchhiker selection works on a similar premise as the split-protein. Yet, in this case the beta-lactamase is not divided into two subunits
but instead its natural export signals are removed. this modified beta-lactamase forms a translational unit with the target protein whilst a signal peptide
for the Tat (Twin-Arginine Translocation) pathway is attached to the Evobody. Only in case of a funtionally binding Evobody to the target protein is the
beta-lactamase exported into the periplasm where it can counteract the ampicillin. Since the Tat pathway only exports correctly folded proteins, this approach also
provides an option to check if the proteins are expressed as we predicted (Waraho, Dujduan & DeLisa, Matthew P. 2009).
In summary, we wanted a selection system to screen for Evobodies with high affinity to the target protein while being functional in vivo. We chose three approaches, of which the bacterial two-hybrid system proved to be the most promising system.
References
Badran, Ahmed H.; Guzov, Victor M.; Huai, Qing; Kemp, Melissa M.; Vishwanath, Prashanth; Kain, Wendy et al. (2016): Continuous evolution of Bacillus thuringiensis toxins overcomes insect resistance. In: Nature 533 (7601), S. 58–63. DOI: 10.1038/nature17938.
Galarneau, Andre; Primeau, Martin; Trudeau, Louis-Eric; Michnick, Stephen W. (2002): Beta-lactamase protein fragment complementation assays as in vivo and in vitro sensors of protein protein interactions. In: Nature biotechnology 20 (6), S. 619–622. DOI: 10.1038/nbt0602-619.
Waraho, Dujduan; DeLisa, Matthew P. (2009): Versatile selection technology for intracellular protein-protein interactions mediated by a unique bacterial hitchhiker transport mechanism. In: Proceedings of the National Academy of Sciences of the United States of America 106 (10), S. 3692–3697. DOI: 10.1073/pnas.0704048106.